Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 52,043 | 6,972 | 8,253 | 10,136 | 10,497 |
| TOTAL | $52,695 | $7,483 | $8,832 | $10,530 | $11,038 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 317 | 347 | 174 | 86 | 172 |
| TOTAL | $317 | $347 | $174 | $86 | $172 |
| Total Assets | $53,012 | $7,830 | $9,006 | $10,616 | $11,210 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 396 | 448 | 297 | 171 | 220 |
| Accrued Expenses | 857 | 459 | 1,512 | 1,475 | 1,148 |
| TOTAL | $1,319 | $907 | $2,108 | $1,646 | $1,435 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 72 | 81 | 0 | 0 | 0 |
| TOTAL | $72 | $81 | $N/A | $N/A | $N/A |
| Total Liabilities | $1,391 | $988 | $2,108 | $1,646 | $1,435 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 56,631 | 45,594 | 45,550 | 41,137 | 40,914 |
| Common Shares | 56 | 45 | 41 | 41 | 41 |
| Retained earnings | -208,373 | -205,308 | -196,215 | -192,866 | -189,820 |
| Other shareholders' equity | 2,260 | 2,260 | 8,942 | 8,952 | 8,952 |
| TOTAL | $51,621 | $6,842 | $6,898 | $8,970 | $9,775 |
| Total Liabilities And Equity | $53,012 | $7,830 | $9,006 | $10,616 | $11,210 |